Liver Biology and Metabolism

Introduction to Liver Biology

The liver is the largest internal organ (approximately 1.5 kg in adults) and performs over 500 known functions: glucose homeostasis (glycogen storage, gluconeogenesis, glycolysis), lipid metabolism (fatty acid synthesis, beta-oxidation, lipoprotein assembly, bile acid synthesis), protein synthesis (albumin, coagulation factors, acute phase proteins, complement), detoxification of drugs and xenobiotics (CYP450 enzymes), ammonia to urea conversion, iron storage (ferritin), vitamin A storage, and immune surveillance. The liver's unique dual blood supply—75% portal blood from the intestine delivering absorbed nutrients, 25% oxygenated hepatic artery blood—places hepatocytes in a privileged metabolic position to process intestinal nutrients before systemic distribution.

The liver has exceptional regenerative capacity—experimental two-thirds partial hepatectomy (PH) in rodents triggers remaining hepatocytes to rapidly re-enter the cell cycle, restoring liver mass in 10-14 days through precisely regulated hepatocyte proliferation. This regenerative ability underlies living-donor liver transplantation (resecting and transplanting a lobe or segment) and the rationale for surgical resection of liver tumours and metastases. Understanding hepatocyte proliferation signals (HGF/Met, EGF-EGFR, Wnt, TNF) and regeneration termination (TGF-beta, bile acid FXR signalling adjusting liver size to body mass) informs cell therapy and liver tissue engineering.

Liver Cell Biology

Hepatocytes and Liver Zonation

Hepatocytes constitute 80% of liver cells by mass. They are extraordinarily metabolically active—containing abundant mitochondria (~2000 per cell), ER (rough ER for protein synthesis, smooth ER for CYP450 drug metabolism), glycogen granules, and lipid droplets. Liver zonation—periportal (zone 1), midzonal (zone 2), and pericentral (zone 3) hepatocyte populations—reflects gradients of oxygen, nutrients, and hormones along the hepatic sinusoid. Periportal hepatocytes preferentially perform gluconeogenesis, fatty acid oxidation, and urea synthesis; pericentral hepatocytes perform glycolysis, lipogenesis, glutamine synthesis, and xenobiotic metabolism. Wnt gradient controlled by pericentral venous endothelium (via endocrine Wnt3/9b) maintains zone 3 identity including CYP450 and glutamine synthase expression.

Kupffer Cells and Liver Immunity

Kupffer cells—the liver's resident macrophages (~15% of hepatic cells)—derive from yolk-sac progenitors maintained by IL-4 signalling and liver-specific environmental imprinting independently of bone marrow monocyte recruitment. They reside in hepatic sinusoids continuously sampling portal blood for pathogens and debris, expressing scavenger receptors (SR-A, CD163) and TLRs detecting PAMPs. Activating Kupffer cells produce TNF, IL-6, and IL-1beta orchestrating liver immune responses against bacteria and gut-derived toxins. Kupffer cell overactivation by LPS from intestinal bacteria (leaky gut in alcoholic liver disease) drives alcoholic hepatitis cytokine storm. NASH progression from simple steatosis to steatohepatitis requires Kupffer cell and macrophage inflammatory activation triggered by DAMPs from lipotoxic hepatocytes.

Non-Alcoholic Fatty Liver Disease

NAFLD and NASH Pathogenesis

NAFLD (non-alcoholic fatty liver disease)—hepatic steatosis without alcohol excess—affects approximately 30% of adults globally, driven by obesity and insulin resistance. Simple steatosis (triglyceride accumulation in hepatocytes) may progress to NASH (steatohepatitis) in 20-30% with hepatocyte ballooning (ER stress), inflammation, and stellate cell activation driving fibrosis. The two-hit model (multiple parallel hits model): insulin resistance drives FFA influx and de novo lipogenesis (hit 1); mitochondrial dysfunction, ER stress, lipotoxicity, gut microbiome dysbiosis, and oxidative stress drive inflammation and fibrosis (second hits). NASH with advanced fibrosis progresses to cirrhosis and hepatocellular carcinoma. Resmetirom (thyroid hormone receptor beta agonist) was FDA-approved in 2024—the first approved NASH treatment—reducing hepatic fat and improving fibrosis in NASH with stage 2-3 fibrosis.

Drug Metabolism and the CYP450 System

Hepatocyte CYP450 enzymes (cytochrome P450 monooxygenases) metabolise ~75% of all drugs—creating water-soluble metabolites for renal excretion, activating prodrugs, or generating reactive metabolites causing hepatotoxicity. Major CYP isoforms: CYP3A4 (30-50% of all drug metabolism; substrate for statins, benzodiazepines, HIV drugs); CYP2D6 (polymorphic—poor/intermediate/rapid/ultra-rapid metaboliser phenotypes affecting codeine, antidepressants, antipsychotics); CYP2C19 (clopidogrel activation—CYP2C19 loss-of-function polymorphisms reduce clopidogrel efficacy in cardiovascular disease). Drug-drug interactions frequently involve CYP450 inhibition (azole antifungals inhibiting CYP3A4) or induction (rifampicin inducing CYP3A4, reducing efficacy of co-administered drugs).

Viral Hepatitis and Liver Disease

Chronic Hepatitis B (HBV, 257 million chronic carriers) and C (HCV, 71 million) are leading causes of cirrhosis and hepatocellular carcinoma (HCC) globally. HCV treatment revolution: direct-acting antivirals (sofosbuvir targeting NS5B polymerase; NS5A inhibitors ledipasvir, velpatasvir; NS3 protease inhibitors) achieve >95% sustained virological response (cure) in 8-12 week oral regimens regardless of genotype—transforming HCV from a chronic progressive disease to a curable infection. HBV treatment: nucleotide analogues (tenofovir, entecavir) suppress viral replication but rarely achieve cure due to cccDNA reservoir; HBV cure strategies targeting cccDNA (CRISPR, siRNA, CAPOSINOBs) are in early development aiming for functional HBV cure.

Examples and Applications

Example 1: Liver Transplantation and Regeneration

Orthotopic liver transplantation cures end-stage liver disease, acute liver failure, and primary liver tumours (within Milan criteria). Living-donor liver transplantation (LDLT) uses the right lobe from a healthy donor whose liver regenerates to near-normal size within 8 weeks through HGF-Met and EGF-EGFR signalling reactivating G0 hepatocytes into G1. Auxiliary liver transplantation—transplanting a partial graft while leaving the native liver in situ—provides bridging while the native liver (e.g., in Wilson's disease after copper chelation) recovers, then gradually removing immunosuppression allows the native liver to repopulate. Understanding liver regeneration signals guides development of growth factor-augmented bridges to support patients awaiting transplantation.

Example 2: Hepatocellular Carcinoma Molecular Biology

Hepatocellular carcinoma (HCC) arises in cirrhotic liver in 80% of cases through accumulation of driver mutations in TERT (promoter mutations 60%), TP53 (30%), CTNNB1 (beta-catenin activating mutations, 30%), ARID1A (10%), AXIN1 (10%). Sorafenib became the first HCC systemic therapy in 2007 (mTOR/VEGFR/PDGFR inhibition—modest survival benefit 2.8 months). Combination atezolizumab (anti-PD-L1) + bevacizumab (anti-VEGF) and nivolumab + ipilimumab have since become first-line options with substantially better survival benefits, established by IMbrave150 and CheckMate 040 trials. HCC surveillance (6-monthly AFP + ultrasound in cirrhotic patients) with curative intent treatment at early stage (resection, ablation, transplantation) is the most effective intervention for mortality reduction.

Example 3: Alcoholic Liver Disease Biology

Alcohol metabolism by ADH1B and ALDH2 generates acetaldehyde (toxic, DNA-damaging) and disrupts NAD+/NADH ratio impeding gluconeogenesis and fatty acid oxidation, causing steatosis. Chronic alcohol induces gut dysbiosis and leaky gut allowing bacterial LPS into the portal circulation; Kupffer cell TLR4 activation by LPS drives TNF production causing hepatocyte injury extending to steatohepatitis. Severe alcoholic hepatitis has 28-day mortality of 25-50%; corticosteroids are the only pharmacotherapy with survival benefit. Liver transplantation for carefully selected patients with severe alcoholic hepatitis (even without sobriety period) improves survival—challenging traditional abstinence requirements. microRNA signatures distinguishing alcoholic hepatitis from NAFLD may improve diagnosis and drug targeting.

Example 4: Hereditary Liver Diseases

Wilson's disease (ATP7B mutations) causes copper accumulation in liver, brain, and cornea—treated by copper chelation (D-penicillamine, trientine) or zinc supplementation blocking absorption. Hereditary haemochromatosis (HFE C282Y mutations) causes iron overload—treated by therapeutic phlebotomy. Alpha-1-antitrypsin deficiency (SERPINA1 Z allele) causes hepatic inclusion bodies from misfolded polymerised AAT protein in hepatocytes and emphysema from AAT deficiency in the lung; liver transplantation cures both manifestations. Gene therapy approaches: CRISPR repair of ATP7B in hepatocytes (early data in animal models), siRNA knocking down Z-AAT production to reduce toxic hepatic inclusions (fazirsiran trial showing inclusion reduction and fibrosis improvement).

Example 5: GLP-1 Receptor Agonists and Liver Fat

GLP-1 receptor agonists (semaglutide, liraglutide)—approved for type 2 diabetes and obesity—substantially reduce hepatic fat content and liver enzyme elevation in NAFLD/NASH, partly through weight loss and partly through direct hepatic GLP-1R effects reducing de novo lipogenesis. Phase III NASH trials of semaglutide showed significant benefit in histological improvement. The cardiometabolic-hepatic connection through GLP-1 pathway illustrates how liver fat accumulation is embedded in systemic insulin resistance and energy homeostasis, not an isolated organ pathology. Understanding the direct hepatic versus systemic weight-loss-mediated GLP-1 effects requires LIVER-specific delivery or receptor-selective analogues targeting GLP-1R in hepatocytes selectively.

Example 6: The Gut-Liver Axis

The gut-liver axis describes bidirectional communication between intestinal microbiome and liver via the portal circulation and bile acid enterohepatic circulation. Bacteria-produced secondary bile acids (deoxycholic acid, lithocholic acid) signal through liver FXR (farnesoid X receptor) and TGR5 receptors regulating bile acid synthesis, lipogenesis, gluconeogenesis, and immune function. TMAO (trimethylamine N-oxide)—produced by gut bacteria metabolising dietary choline and L-carnitine—is a cardiovascular risk factor whose level reflects gut microbiome composition. Dysbiosis in NASH (increased Gram-negative bacteria, higher LPS portal burden, reduced butyrate producers) drives Kupffer cell activation. FXR agonist obeticholic acid—targeting bile acid signalling in liver—showed anti-fibrotic effects in NASH (Phase III REGENERATE trial).

Example 7: Liver Organoids and Drug Testing

Liver organoids derived from ductal hepatic progenitor cells (Lgr5+ cholangiocytes in periportal niche) or iPSC differentiation are used for disease modelling and drug toxicity testing. EpCAM+ cholangiocyte-derived organoids can be differentiated into functional hepatocyte-like cells expressing CYP450 enzymes, albumin, and glycogen synthesis, enabling patient-specific hepatotoxicity modelling. Microphysiological systems (liver-on-chip) couple hepatocytes with Kupffer cells, stellate cells, and sinusoidal endothelium under physiological flow replicating NASH pathophysiology ex vivo. These systems screen NASH drug candidates at human tissue level—improving translation over rodent models that fail to recapitulate human NASH inflammatory and fibrotic progression accurately.

Example 8: Cholestasis Molecular Biology

Cholestasis—impaired bile flow causing toxic bile salt accumulation—results from ABCB11 mutations (PFIC2, progressive familial intrahepatic cholestasis type 2) impeding bile salt export pump function; ABCB4 mutations (PFIC3) impairing phospholipid export causing toxic, un-buffered bile salt injury to cholangiocytes; or acquired causes (intrahepatic cholestasis of pregnancy, drug-induced cholestasis). ABCB4 deficiency is treated by ursodeoxycholic acid protecting cholangiocytes and diluting toxic bile; PFIC2 is partially responsive to ursodeoxycholic acid, with liver transplantation as definitive treatment. NPC1L1 (cholesterol absorption) and NTCP (HBV entry receptor) are additional bile acid transporter drug targets—understanding their biology enabled discovery of ezetimibe and bulevirtide respectively.

Try it live

Everything above runs in your browser — open Liver Biology and Metabolism: Hepatic Lobule Simulator and change the parameters while it is running. Nothing is installed, nothing is uploaded, the whole model lives in one tab.